EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders

Adnan Akif iD, Nigar Sultana iD, Ishtyaque Mikrani iD

International Journal of Endocrinology · 2026-01 · 2026 (1)

DOI: 10.1155/ije/7761643 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Endocrinology, online erschienen am 09.11.2026. Verfasst von Adnan Akif und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology & Cell Biology School of Medicine University of Nevada Reno Nevada USA unlv.edu. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota (GM) modulates host energy balance, glucose–lipid metabolism, and enteroendocrine signaling through metabolite–receptor axes that include short‐chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino‐acid/choline‐derived compounds such as imidazole propionate (ImP) and trimethylamine N‐oxide (TMAO). These pathways regulate incretin biology (GLP‐1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug–microbiome interactions (GLP‐1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile‐acid and SCFA pathways. Together, these findings support precision strategies that profile GM–metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.

Schlagwörter

Stichwörter der Autor:innen

diabetesfecal microbiotagut microbiotainflammatory bowel diseasemetabolite

Autor:innen und Institutionen

  • Department of Physiology & Cell Biology School of Medicine University of Nevada Reno Nevada USA unlv.edu.
  • Sir Salimullah Medical College Dhaka Bangladesh.
  • Department of Pharmacy National Model College for Advance Learning Tribhuvan University Kathmandu Nepal tribhuvan-university.edu.np.

ORCID-Profile: Adnan Akif, Nigar Sultana, Ishtyaque Mikrani

Zitieren

APA

Akif, A., Sultana, N., & Mikrani, I. (2026). The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders. International Journal of Endocrinology, 2026(1). https://doi.org/10.1155/ije/7761643

Vancouver

Akif A, Sultana N, Mikrani I. The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders. International Journal of Endocrinology. 2026;2026(1). doi:10.1155/ije/7761643

BibTeX
@article{Akif2026,
  author = {Akif, Adnan and Sultana, Nigar and Mikrani, Ishtyaque},
  title = {The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders},
  journal = {International Journal of Endocrinology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ije/7761643}
}
Kostenlos starten →